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Metabolic sensorThe second messenger cyclic adenosine 3′,5′-monophosphate (cAMP) regulates a wide range of physiological
processes in almost all organisms. cAMP synthesis is catalyzed by adenylyl cyclases (ACs). All ten mammalian
AC isoenzymes (AC1–10) belong to AC Class III, which is deﬁned by sequence homologies in the catalytic
domains. Nevertheless, the mammalian AC can be separated into two distinct types, nine transmembrane
enzymes (tmAC; AC1–9) and one soluble AC (sAC; AC10). tmACs are mainly regulated by heterotrimeric
G-proteins as part of the G-protein coupled receptor pathways, while sAC is directly activated by bicarbonate
and Ca2+ and acts as a sensor for ATP, Ca2+, and bicarbonate/CO2/pH at various intracellular locations.Mammalian
sAC has been implicated in processes such as sperm activation, glucose metabolism, and prostate and skin cancer,
making it a potential therapeutic target, and ﬁrst sAC-speciﬁc inhibitors have been developed. Mammalian sAC
appears evolutionarily closer related to microbial Class III ACs than to tmACs, and sAC-like bicarbonate activated
ACs are indeed found in lower organisms and can contribute, e.g., to virulence regulation in microbial pathogens.
Here, we review work on the architecture, catalysis, and physiological and pharmacological regulation of sAC-like
enzymes, with a main focus on the mammalian enzyme. We further compare the biochemical, regulatory, and
structural characteristics of sAC-like enzymes to the evolutionarily and structurally related mammalian tmACs,
pointing out common features as well as sAC-speciﬁc properties and modulators. This article is part of a Special
Issue entitled: The role of soluble adenylyl cyclase in health and disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cyclic adenosine 3′,5′-monophosphate (cAMP) was discovered as a
signaling molecule in the 1950s during studies on hormonal regulation
of mammalianmetabolism [1]. Subsequent studies described cAMP as a
prototypical second messenger, which passes on signals reaching the
cellular membrane to intracellular targets [2]. cAMP is found in all
domains and kingdoms of life – only its occurrence in plants is still not
fully clariﬁed – and it contributes to a very wide range of physiological
processes, from virulencemechanisms in bacteria and fungi tometabol-
ic regulation and transcription in mammals [3–6]. cAMP targets distinctthylene-adenosine-5′-triphos-
catechol estrogen; DIDS, 4,4′-
in,βandγsubunits;GC,guanylyl
oryG protein,α subunit;MANT,
;PKA,proteinkinaseA; sAC, sol-
lyl cyclase; sACﬂ, full-lengthsol-
mbrane adenylyl cyclase
e of soluble adenylyl cyclase ineffector proteins in the different kingdoms. In Escherichia coli, the
transcription factor “catabolite gene activator protein” (CAP), also
known as “cAMP responsive protein” (CRP), acts as a major effector
[3]. In mammalian cells, at least four types of cAMP effectors are
known: protein kinase A (PKA), cyclic nucleotide gated ion channels
(CNGs and HCNs), small G-protein regulating “exchange proteins
activated by cAMP” (EPACs), and phosphodiesterases (PDEs) [3,7].
Cellular levels of cAMP are controlled through its synthesis by
adenylyl cyclases (AC; EC 4.6.1.1) and its degradation by PDEs [4,5,8].
AC enzymes catalyze an intramolecular cyclization of ATP to cAMP
under release of pyrophosphate (see Section 2.2.2) [4]. ACs, and
the guanylyl cyclase (GC) enzymes generating the related second
messenger cGMP from GTP, form the nucleotidyl cyclase family, which
comprises six evolutionary distinct classes deﬁned by sequence homol-
ogieswithin their catalytic domains [4,9]. The AC from E. coli and several
AC enzymes from related gram-negative prokaryotes belong to Class I
[4]. Class II comprises secreted “toxin” ACs from pathogens such as
Pseudomonas aeruginosa and Bordetella pertussis, which translocate
into host cells and disrupt intracellular signaling [6]. All known eukary-
otic nucleotidyl cyclases, ACs and GCs, belong to the ubiquitous Class III,
which also comprises AC from many prokaryotes and all known GC
[4,9]. The Classes IV–VI were deﬁnedmore recently and so far comprise
only one or few prokaryotic members [4].
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simultaneously in many tissues and organisms, reﬂecting the variety
of cellular processes regulated by cyclic nucleotides. In mammals,
there are tenAC genes encodingdifferently regulated AC isoforms called
AC1 to AC10 [5,10]. AC1–9 form an extensively studied subfamily of
so-called transmembrane ACs (tmACs). Mammalian tmAC activity is
mainly regulated by heterotrimeric G proteins upon activation of
G protein-coupled receptors (GPCRs) by extracellular hormones and
neurotransmitters [10]. The different tmAC isoforms contribute to
distinct physiological activities, such as AC1 to memory formation [11]
and AC5 to cardiac myocyte function [12]. A second type of AC, referred
to as “soluble AC” (sAC), is encoded by the AC10 gene [4]. Amammalian
sAC activity was discovered in the 1970th but more intense studies
commenced only after isolation of the ﬁrst sAC cDNA in 1999 [13,14].
Signiﬁcant progress in recent years revealed that sAC activity is sensitive
to variations in physiological ATP levels and that sAC enzymes are
directly activated by Ca2+ and the metabolite bicarbonate, rendering
them intracellular metabolic sensors and signal integrators [15–19].
Mammalian sAC is expressed in many tissues [20,21] and resides in
discrete cellular locations, such as the nucleus and mid-bodies [22].
Physiological functions regulated by sAC are, e.g., sperm motility [23],
pH regulation [24], apoptosis [25], and metabolic pathways such as
glycolysis and mitochondrial respiration [26–28]. AC enzymes with
sAC-like regulation, in particular activation by bicarbonate, have also
been described in lower organisms and even in bacteria [4,29,30],
suggesting an evolutionary conserved family of sAC-like, bicarbonate-
sensing Class III ACs.
Mammalian sAC has been implicated in glucose-induced insulin
release and in prostate and skin cancer, suggesting it as a therapeutic
target for the treatment of type 2 diabetes and cancer [18,31–33]. It is
also used as a target for male contraceptives and as a diagnostic marker
for melanoma [34,35]. The contribution of sAC-like ACs to virulence
regulation in pathogens such as Candida albicans and P. aeruginosa
renders them potential targets for antifungal and antibiotic compounds
[30,36]. Speciﬁc modulators for sAC-like enzymes are therefore tools forFig. 1.Domain architecture of mammalian tmAC and sAC. (a) Some of the general architectures
centers because both catalytic domains can contribute conserved catalytic residues typical for C
structurally similar catalytic domains on one polypeptide. C1 and C2 contribute only a speciﬁc su
pocket. (b) Scheme of the domains and sequence regions in mammalian sAC. The domains/regfunctional studies but also potential lead compounds for thedevelopment
of therapeutic drugs.
Architecture, catalysis, and physiological and pharmacological
regulation of Class III tmACs and sACs have been studied biochemically
and structurally, revealing common features as well as properties and
modulators speciﬁc for one of the two related AC types. Here, we review
biochemical, regulatory, and structural characteristics of sAC-like en-
zymes, with a focus on the mammalian members, and compare them
to tmACs.
2. sAC and sAC-like ACs— speciﬁc features and comparison to tmACs
2.1. Class III AC domain architecture
All eukaryotic ACs belong to Class III, which is deﬁned by a conserved
~200 residue catalytic domain [4,9]. A series of crystal structures of Class
III AC and GC catalytic cores revealed a conserved dimeric architecture
[4,19,37–41]. There are either two Class III catalytic domains, normally
referred to as C1 and C2, on one polypeptide chain and form a pseudo-
heterodimer, or there is one catalytic domain per polypeptide that
homodimerizes with a second copy (Fig. 1a). Most bacterial ACs and
mammalian receptor GCs are homodimers, which feature two symmet-
rical active sites at the dimer interface. Mammalian tmACs and sACs
have the tandem arrangement of two homologous and structurally
similar catalytic domains C1 and C2 forming a pseudo-heterodimer
(from now on referred to as heterodimer). C1 carries only a subset of
the catalytic residues and C2 a complementary set of essential residues,
so that only one of the pseudo-symmetric interface sites is active
(Fig. 1a). It appears that C1 and C2 evolved through gene duplication
and subsequent degeneration of the second site into a regulator binding
site (see Refs. [4,19,42] and Section 2.4.1).
Class III AC catalytic domains appear to constitute a versatile signaling
module that is fused to a variety of regulatory domains in different
AC enzymes, enabling them to serve as sensors and signaling enzymes
for many different stimuli [43]. This variety is particularly obvious inof Class III nucleotidyl cyclases. Homodimeric enzymes feature two symmetric, fully active
1 and C2 (they are therefore labeled as C1/2 domains). Mammalian tmAC and sAC carry two
bset of the catalytic residues, resulting in one active site and a pseudo-symmetric, inactive
ions are not drawn to scale, residue numbers given at the bottom refer to human sAC.
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metabolic adaptation to virulence [6]. The mycobacterial Class III AC
Rv1625c is an example for a more tmAC-like microbial enzyme [44].
However, microbial ACs appear generally more closely related to sAC
than to tmACs (see Refs. [4,45] and Section 2.3), and even several
sAC-like bicarbonate-activated ACs have been identiﬁed in microorgan-
isms. The sAC-like AC in Cryptococcus neoformans, e.g., features Leu-rich
repeats and a protein phosphatase-like domain and integrates signals
such as bacterial peptidoglycans and CO2 levels to regulate environ-
mental adaptations and virulence [30,46]. CyaB, a sAC-like AC from
P. aeruginosa, features an N-terminal “membrane-associated sensor 2”
(MASE2) domain and integrates CO2 sensing with regulation through
a Chp chemosensing system [36,47]. Many other regulatory modules
can be found fused to Class AC catalytic domains [43]. Themycobacterial
ACRv1264 is regulated by apH-sensingdomain [48], and small-molecule
binding modules such as GAF (ﬁrst identiﬁed in cGMP-binding PDE, AC,
and the E. coli transcription factor FhlA) domains make AC responsive
to regulators such as cGMP [43]. However, the ligand is not known for
many of these AC regulating domains.
Mammalian AC isoforms also comprise signiﬁcant protein regions
outside the catalytic domains. They likely serve regulatory functions
but might also contribute to intracellular localization. Among the
mammalian AC, the nine tmACs feature variable N-terminal regions,
followed by a six transmembrane (tm) helices domain (tm1), the ﬁrst
catalytic domain C1a, a second six transmembrane helices domain
(tm2), and the second catalytic domain C2a (Fig. 1a) [4,49]. Linker and
tm regions likely provide additional functions other than membrane
anchoring and fusing different protein parts. However, little is known
beyond a function of the C1b linker fusing C1a to tm2 in regulation
by free Ca2+ and by Ca2+/calmodulin and a likely contribution of
N-terminus and the C2b region C-terminal from C2a to Ca2+/calmodulin
recognition. In sAC, the catalytic domains C1 and C2 are positioned at the
N-terminus and connected by a ~68 residue linker that forms a death
domain like subdomain with the ~33 residue N-terminal tail of the
protein (Fig. 1b) [19]. C-terminal from this C1–C2 tandem, full-length
mammalian sAC comprises a ~1100 residue C-terminal region (CTR),
mostly with little understood function and apparently without a tm
region (Fig. 1b) [4]. The sAC-CTR starts with a small motive mediating
an autoinhibitory effect (see Ref. [50] and Section 2.4.1). It likely acts
together with other sAC-CTR domains, such as the neighboring putative
NTPase domain. p NTPase-like domain and weak sequence similarities
further C-terminal, sACwas suggested to belong to the “signal transduc-
tion ATPases with numerous domains” (STAND) family [51,52].
In STAND proteins, such as the apoptosis regulator Apaf-1 and the
transcriptional activator MalT, intrinsic NTPase activity regulates the
protein's signaling status through conformational changes in linker
and/or effector domains. In MalT, e.g., a NTPase domain and a tetratrico
peptide repeat (TPR)-related domain enable ATP and maltotriose to
induce activation through the modulation of interactions with an
inhibitory protein and of MalT oligomerization [52–54]. Its intrinsic
ATPase activity switches MalT off again [52]. Besides the NTPase-like
domain, the sAC-CTR contains three regions with putative TPRmodules
[20], but a MalT- and STAND-related regulation of sAC remains to be
conﬁrmed. Physicochemical sequence analysis and expression of sAC
fragments in E. coli in fact revealed a domain that can bind a heme ligand
and that covers part of the ﬁrst predicted TPR region, making a TPR-like
structure less likely [20]. This sAC heme-binding domain (sAC-HD)
shows no sequence similarity to the heme domain of the related Class
III enzyme soluble guanylyl cyclase (sGC), which acts as physiological
receptor for the activator nitric oxide (NO). The sAC-HD instead might
be remotely related to PAS domains, which are also found in bacterial
Class III AC and sGC [43,55], or it might represent a novel heme domain
type [20]. Nevertheless, NO and another potential gaseous signaling
molecule, carbon monoxide (CO), can bind to sAC-HD. A variety of sAC
isoforms comprising different CTR parts appears to be generated
through alternative splicing (see Refs. [56,57] and Section 2.4.1),and sAC species comprising the HD are found at least in testis and
skeletalmuscle [20]. sAC-HD thusmakes sAC a candidate for themissing
link between NO and cAMP signaling, e.g., in sperm cells [58,59].
However, the physiological interaction partners and/or functions of
sAC-HD remain to be clariﬁed. For the remaining sAC-CTR, where no
well deﬁned sequence motifs and homologies have been identiﬁed
besides the features discussed above, we also have to await further
studies to understand how they contribute to the regulation of sAC
activity and localization.
2.2. Catalytic domain structure and catalyticmechanism - general and sAC-
speciﬁc features
2.2.1. Catalytic domain structure
The ﬁrst crystal structure for an active Class III AC catalytic core, a
heterodimer of a mammalian tmAC5-C1 and tmAC2-C2 domain [42],
revealed a head-to-tail arrangement of these structurally similar do-
mains resulting in a compact core. This arrangement was subsequently
conﬁrmed as general Class III setup through crystal structures of a
variety of AC and GC catalytic cores [4,37–40], including the bacterial
sAC-like AC CyaC [17]. Only recently, crystallization and structure
solution were reported for the mammalian sAC catalytic core (sAC-cat)
and several sAC-cat ligand complexes [19,45,60,61]. The structure of
this human sAC-cat will now be described in order to provide informa-
tion on the architecture of a typical Class III cyclase catalytic core, and
sAC speciﬁc features will be explicitly pointed out and compared to
tmACs.
The overall sAC-cat structure shows the typical Class III pseudo-
heterodimer arrangement of structurally similar C1 (residues 34–219;
numbering refers to human sAC if not stated differently) and C2
(288–463) domains (Fig. 2a, top left; C2 residues and secondary struc-
ture elements are labeled by an asterisk) [19]. Both domains feature
the generic Class III monomer fold with a central seven-stranded β-
sheet shielded from solvent by helices α2, 3, and 5 [4,37]. The dimer is
stabilized through a clamp-like extension formed by the β4 C-
terminus and β5 strand of both pseudo-monomers. Interestingly, mo-
lecular replacement phasing with the available Class III AC structures
was not successful and the sAC-cat structures had to be solved using ex-
perimental phasing strategies [19,61]. However, only small differences
in overall structure to other Class III ACwere identiﬁed. sAC-speciﬁc fea-
tures are its short N-terminal extension and the C1–C2 linker. The ~33
residue region N-terminal from C1 forms an extended tail (residues
1–12) and two additional α-helices (αN1, αN2; Fig. 2a, right). With
two of the three α-helices in the ~68 residue C1–C2 linker (αL1-3),
they form a death domain-like four helix bundle (NLH-bundle) [19].
This linker startswith three consecutive Pro (220–222), located at a cor-
ner of the core particle and next to a partially solvent accessible hydro-
phobic patch. Part of the hydrophobic surface interacts with the N-
terminus of a symmetry related monomer, and these sAC regions have
been speculated to serve as interaction sites for other proteins or sAC do-
mains in solution [19].
The active site of the Class III cyclase catalytic core, with seven highly
conserved catalytic residues, is located at one pole of the pseudo-dimer
interface and formed by residues from both, C1 and C2 (Fig. 2a,b).
However, C1 and C2 provide distinct catalytic residues, and since C1
lacks essential C2 residues and the other way round, the pseudo-
symmetric site at the other pole of the dimer interface is inactive and
instead serves as a regulatory site (see Section 2.4.1). In the active site,
two conserved Asp residues (Asp47 and Asp99) form binding sites for
two divalent ions, ion A and ion B (Fig. 2b). The ion sites are normally
occupied by Mg2+ and contribute to substrate binding (ion B) and
turnover (ion A), respectively (see Section 2.2.2). Ion A and Arg416*
interact transiently with the α-phosphate (see Section 2.2.2), while
ion B is coordinated by the β- and γ-phosphates, which are further
bound by main chain atoms at the α1 N-terminus and by polar side
chains (Ser49, Thr52, Asn412). A mainly hydrophobic cleft formed by
Fig. 2. Structure of the sAC catalytic core and comparison to tmAC. (a) Crystal structure of the human sAC-cat complexwith the substrate analog ApCpp (PDB ID: 4CLK) in two orientations.
The front view (left) shows the entrance to active site (containing the substrate analog in stick presentation; upper right) and regulatory pocket (containing chloride as green sphere;
lower left) formed at the interface of the C1 (cyan) and C2 (blue) domains. The side view (right) shows the death domain like helix bundle on the back of the pseudo-heterodimeric
core, formed by helices from N-terminus (magenta) and C1–C2 linker (gray), respectively. Only selected secondary structure elements are labeled. For comparison, a front view of a
tmAC/ATPαS/forskolin complex (1CJK) is shownbelow sAC. The boundGsα protein (positioned at the lower left tmAC corner) is omitted for clarity. (b) Active site of a sAC/ApCpp complex
(4CLK). The ATP analog and catalytically important residues are shown in stick presentation. The Ca2+ in the ion B site is shown as a yellow sphere, and themissing ion A is indicated by a
dotted circle. (c) Overlay of the sAC/ApCpp complex (cyan; 4CLK) with apo sAC (green; 4CLF), showing that Asp99 moves away from Arg176 to allow binding of nucleotide and ion B.
Selected residues are shown in stick presentation, ion B as a sphere.
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substrate base, and adenine is supposed to be recognized through two
polar interactions, between Lys334 and the ring nitrogen N1 and be-
tween Thr405 and the 6-amino group, which further forms two main
chain contacts (Fig. 2b). These interactions are considered the major
determinants for the ATP or GTP speciﬁcity of Class III AC and GC, re-
spectively [4,62]. The Lys334 interaction is not seen in the available
sAC-cat/nucleotide complexes and might be transient (see
Section 2.2.2). The Thr appears typical for sAC-like AC and is func-
tionally replaced by Asp in most other Class III AC [4,62]. The Thr
(can act as H-bond donor and acceptor) has been speculated to
cause the signiﬁcant GC side activity of sAC, since it appears to enable
a GTP binding mode excluded by Asp (obligate H-bond acceptor)
[45]. Also other residue combinations have been observed in micro-
bial AC [62]. In mammalian GC, the Lys and Thr/Asp are replaced by
Glu and Cys, respectively, adapting the residues to the H-bond
donor/acceptor pattern of guanosine. Mutating these positions
converted Class III cyclase speciﬁcity in some cases but not in others[4,62,63]. Additional factors thus appear to contribute to substrate
selection, such as sterical complementarity between base and active
site and the dimer arrangement, which is inﬂuenced by these
residues due to the dimer interface location of the active site [38,64].
The substrate ribose also occupies a mainly hydrophobic pocket and
only forms a polar contact with its ring oxygen to Asn412. In tmACs, the
ring oxygen further appears to interact with a conserved Ser (Ser1028*
in tmAC2-C2) that is replaced by a conserved Ala in sAC-likeAC (Ala415*
in hsAC). This difference is speculated to be relevant for the lower ATP
afﬁnity characteristic for sAC-like AC [17].
Interestingly, in the sAC-cat apo structure Asp99, one of the two
conserved Asp, is shifted from its ion coordinating position (Fig. 2c).
An Asp side chain rotation opening the ion sites had previously been
observed in the bacterial GC Cya2 [38] but in sAC, the whole active
site loop β2/3 comprising Asp99 is signiﬁcantly shifted toward the
sAC-speciﬁc residue Arg176, resulting in a Arg176/Asp99 salt bridge
and an overlap of the β2/3-loop with the ion sites [19]. Comparison to
a sAC-cat/ATP analog complex structure shows no major differences
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prising the two conserved Asp (Fig. 2c). A partial unwinding of the
small, catalytic helix α1 [17,42] releases the interaction between the
backbone of Ser49 and Asp47, allowing the Asp to tilt into position for
ion binding. The necessary space is opened up through a β2/3-loop
rearrangement, which further reorients Asp99 away from Arg176 and
in position for substrate binding. The thereby formed ion B site is occu-
pied by a Ca2+ ion (see Sections 2.2.2 and 2.4.1) in the sAC-cat/ApCpp
complex [19]. This substrate-induced active site rearrangement has
not been observed for tmACs and might contribute to the lower ATP
afﬁnity of sAC-like AC (see Sections 2.2.2 and 2.4.1).
2.2.2. General catalytic mechanism of Class III AC and sAC-speciﬁc features
Overall structure, active site architecture, and residues involved in
substrate binding and catalysis are conserved or show only functionally
conserved substitutions in Class III cyclases (see Refs. [4,38] and the
structure-based comparison and alignment in Ref. [45]), suggesting
that only small variations from a generic catalytic mechanism occur in
this enzyme family. The widely accepted Class III mechanism, initially
suggested based on stereochemical studies and now supported by
many biochemical and structural data, involves an intramolecular attack
of the substrate's ribose 3′-hydroxyl group at Pα and simultaneous
release of Pβγ (Fig. 3a) [4,65]. This pseudo-binuclear nucleophilic
substitution (SN2) mechanism with an in-line arrangement of the
attacking 3′-OH and the Pα-O bond being broken implies a pentavalent
transition state with an additional negative charge at Pα, which is
stabilized by ion A and Arg416* (Fig. 3a). Ion A is therefore called the
catalytic ion. Due to this temporary completion of the ion A site,
this ion appears to bind transiently during catalysis and is rarely
observed in AC/substrate analog complexes, most likely only when a
non-productive nucleotide conformation assists in an artiﬁcial ion A
coordination [17,66]. In a CyaC complex with Rp-ATPαS, the thio-
modiﬁcation causes an non-productive α-phosphate orientation
resulting in a stable complex with ion A, whereas in CyaC and sAC
complexeswith Ca2+/ApCpp, the triphosphate assumes a conformation
suitable for the in-line reaction and no ion A is bound [17,19]. Ion AFig. 3. Catalytic mechanism of Class III AC. (a) Catalytic mechanism of Class III AC, with residue
the divalent cation in the ion B site (here shown as Ca2+). The substrate base and the α-phosp
respectively. Arrow:Movement ofα-phosphate. (b) Active site closuremovement of Class III AC
and ATPαS in presence of bicarbonate (magenta; 1WC6) shows that the β7/8-loop and α1 (cimight also contribute to deprotonation of the attacking 3′-hydroxyl, ei-
ther directly or through aMg2+-activated watermolecule [4,17,66]. Ion
B contributes to binding, and possibly proper orientation, of the ATP
substrate through interactions with Pβ and Pγ [17,19,66], and Ca2+ ap-
pears to enable a stronger interaction than Mg2+ in this site (see
Section 2.4.1). The γ-phosphate is further bound by Asn412, Thr52,
and several backbone atoms in a pocket at the α1 N-terminus, and the
β-phosphate also interacts with the α1 N-terminus, via Ser49 and the
Ile48 carbonyl oxygen. This phosphate binding mode is generally seen
in Class III cyclase complexes with NTPs [4,37], only the substrate-induced
formation of this phosphate-binding pocket, along with ion sites, through
partialα1 unwinding (see also Section 2.2.1) has so far only been observed
for sAC-cat [19]. The requirement of an active site rearrangement in sAC
might contribute to its lower ATP afﬁnity compared to tmACs (see
Section 2.4.1). In the sAC/ApCpp complex, the α-phosphate already in-
teracts with Arg416*, the conserved Class III residue that will stabilize
the transistion state (see above), while no such interactionwith the sub-
strate ground state is assumed for tmACs/nucleotide complex, but it re-
mains to be seen whether this contact is also formed with ATP rather
than an analog [19,42]. In sAC, Arg176 is positioned opposite the ribose
hydroxyls and might facilitate the deprotonation of the 3′-OH.
Structures of sAC-cat in complex with the products cAMP and PPi,
alone and in combination, show binding modes for the nucleoside
and the β/γ-phosphates that are very similar to those with substrate
analog [19]. It thus appears that they do not move signiﬁcantly during
catalysis and suggest that product formation proceeds mainly via an
α-phosphate movement toward the 3′-OH (Fig. 3a). However, the
conserved adenine-recognizing residue Lys334 interacts with the base
of substrate and product, respectively, only indirectly via a water mole-
cule. It indeed appears that the full interactions required for base recog-
nition are formed only after initial binding of the nucleotide, since
binding afﬁnities of sAC and the bacterial GC Cya2 for their substrate
and the respective other nucleotide are similar, yet turnover rates differ
[19,38]. Soaking of sAC-cat crystals with ATP shows that the sAC retains
its activity within the crystal lattice, so that a transient Lys334/adenine
interaction has to be assumed [17,19]. Similar to the sAC/nucleotidenumbers referring to human sAC. A major interaction for substrate binding is mediated by
hate appear to form transient interactions with Lys334 and ion A (here shown as Mg2+),
. An overlay of CyaC in complexwith ApCpp (green; PDB ID: 1WC0), ATPαS (cyan; 1WC1),
rcled) move from open to closed to further closed positions.
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[67], suggesting that such a transient nucleotide discrimination during
turnover is a general Class III cyclase feature. In contrast, the Lys/adenine
interaction is observed in several AC complexeswith ATP-analogs [4,37],
but it might be visible because of a slightly shifted position of the
artiﬁcial, reaction-incompetent substrate analog. It is tempting to specu-
late that a temporary shift of the substrate AMP moiety toward the
conserved base-recognizing Lys supports elongation and ultimate
breaking of the covalent bond between α- and β-phosphate (Fig. 3a).
Lys144, located at the other end of the active site cleft, appears to act
as a “PPi receptor”, helping to keep the terminal phosphates in position
or even slightly tearing Pβ away from Pα.
In the sAC/cAMP complex, the product phosphate position appears
to clash with the ionA site, likely contributing to the transient binding
of this ion [19]. The cAMP product then appears to be released ﬁrst.
PPi binds with higher afﬁnity [19] and its release has in fact been
observed to be rate-limiting for tmACs under certain conditions [68].
A reorientation of Asp399* and the surrounding β2/3* active site loop
was observed upon formation of the trimeric complex of sAC-cat with
the two products cAMP and PPi and is speculated to constitute an
enzyme state involved in catalysis or product release [19]. A steric
clash with Asn412 is another mechanism suggested to contribute to
product release [37], but its relevance also remains to be conﬁrmed.
An active site closure movement of two structural elements,α1 and
a β7/β8 module, appears to contribute to Class III AC catalysis [4,17,42].
It was ﬁrst proposed as a substrate-induced active site closure [42].
An alternative model was later based on CyaC structures and the
substrate analog ApCpp, which might be a better substrate analog for
AC than other nucleotides because it allows proper alignment of the
3′-hydroxyl and the bond to be broken (see above) [17]. In this model,
substrate binding actually opens the active site further before the
closuremovement then contributes to substrate turnover by supporting
separation of the α- and βγ-phosphates [17] (Fig. 3b). Product
dissociation would ﬁnally release the interactions to α1 and β7/8 and
allow active site opening. Consistent with such an opening upon PPi
release, tmAC complexes with P-site inhibitors (adenosine derivatives
requiring a polyphosphate tail or pyrophosphate for efﬁcient inhibition;
see Section 2.4.2), which are assumed to resemble enzyme/product
complexes, show a closed enzyme conformation [42,66,69]. However,
the series of sAC-cat complex structures with various ligands, including
substrate analog and products from substrate turnover, are all obtained
with the same crystal form and in a rather closed conformation [19].
Crystal packing might restrict the conformations accessible to the
protein, but it retains full activity in the crystals and thus appears to
be able to access all states necessary during catalysis [19,45]. The
substrate-induced active site opening thus might be more local in sAC,
making it compatible with the packing, and it might occur more
transient before a closure as proposed in the initial model. However,
the exact role of the open/closed transition of α1 and the β7/8 module
and identiﬁcation of the dynamic active site processes during substrate
binding and turnover clearly require further studies.
Interestingly, Class II ACs are structurally unrelated to Class III
enzymes but appear to employ a related catalytic mechanism. The
monomeric Class II catalytic domains have a single active site with
two ion binding sites, which appear to functionally resemble the Class
III ion A and ion B sites [70]. Similarly, a Class III-like mechanism with
an in-line SN2 reaction catalyzed by using two divalent cations is
assumed for Class IVAC [71]. Since Class II, III, and IV showno signiﬁcant
similarity in their overall structure, it is assumed that their common
mechanistic features are the result of a convergent evolution process
[71].
2.3. Evolution of mammalian AC and Class III subfamilies
Class III AC catalytic cores are assumed tohave evolveddivergently [9].
They are fused to a large variety of regulatory domains (see Section 2.1)and show recognizable homology but low overall sequence identity
[9,43], suggesting that theymight be evolutionary old. Only few positions
are strictly conserved, because they are critical for the general structure of
Class III AC or because they directly contribute to catalysis [4,43]. Even
among the catalytic residues, such as the speciﬁcity-determining residues,
functionally conservative substitutions are seen (see Section 2.2.1). Based
on such positions, four Class III subclasses have been deﬁned [43].
sAC was proposed to be most ancient among the mammalian
cyclases based on a higher catalytic core sequence similarity to ACs
from cyanobacteria and myxobacteria than to other mammalian
cyclases [4,14]. To form C1–C2 cyclases, such as mammalian sAC and
tmAC (see Section 2.1), a homodimeric primordial cyclase apparently
underwent gene duplication and diversiﬁcation, and evolutionary
closeness to bacterial or mammalian cyclases appear even distinct for
sAC's C1 and C2 domain [4,72]. Including the growing number of avail-
able crystal structures in such comparisons has revealed previous
alignment errors but supports a closer relationship of bacterial AC to
sAC than to tmACs, although no larger structural features speciﬁc for
subfamilies and thus deﬁning such relationships are evident (see Ref.
[45] and Section 2.2). Further evolutionary details will likely require ad-
ditional Class III AC crystal structures and careful correction of sequence
alignments. However, mammalian sAC forms a cAMP signaling system
with PDE2 and PKA in the matrix of mitochondria [28,73,74], which
are assumed to have evolved from proteobacteria, and this metabolic
regulation function is speculated to constitute an evolutionary early
acquired role of sAC [75]. Also, mammalian sAC and several bacterial
Class III ACs are similarly regulated by bicarbonate and Ca2+ (see Refs.
[4,16,17,29] and Section 2.4.1), suggesting an evolutionary closeness.
Another indication for such a closeness are bacterial ACs with similari-
ties to the sAC-CTR, such as a mycobacterial AC and three Chloroﬂexus
proteins that feature a P-loop containing putative NTPase domain
C-terminal from C2 (see Section 2.1) [72,76].
sAC-like ACs were identiﬁed in the genomes of many eukaryotic
organisms, but only few of them have been cloned and further studied.
sAC gene has been reported for chicken, ciona intestinalis, corals,
mosquito, honey bee, dogﬁsh, and all mammals analyzed (human,
chimpanzee, dog, cow, rabbit, mouse, and rat) [4,77,78]. Surprisingly,
a sAC-like gene has not yet been identiﬁed in other organisms, including
thewidely usedmodel organisms Caenorhabditis elegans andDrosophila
melonogaster, and it has been speculated that these lineages lost their
sAC-like cyclase during evolution [79]. The physiological relevance of a
second sAC-like locus in the genomes of human, chimpanzee, dog, and
cow remains to be clariﬁed [4].
Appearance of G-protein responsive tmACs starts only in metazoans,
but related cyclases not regulated byG-proteins have been characterized
fromMycobacterium tuberculosis and protozoans [80,81]. However, most
microbial ACs appear either more closely related to sAC or not closely
related to either sAC or tmACs. Conversely, fungal ACs appear to feature
properties from both sAC and tmAC, although they seem to form a sep-
arate branch in the Class III cyclase phylogenic tree [4]. The AC enzymes
from Saccharomyces cerevisiae and from the pathogenic fungi C. albicans
and C. neoformans are regulated by G-proteins [82,83], but they lack
obvious tm regions and are also regulated by bicarbonate [84].
2.4. Regulation of sAC-like AC
Like other signaling enzymes, Class III ACs are highly regulated,most
often through various signals and mechanisms such as small-molecule
ligands, posttranslationalmodiﬁcations (PTMs) and regulatory proteins.
The regulation of sAC-like AC clearly distinguishes them from tmAC and
other Class III AC. sAC-like ACs show an increase in apparent ATP afﬁnity
in presence of Ca2+, and their turnover rates are increased by bicarbon-
ate [16,17,29]. Mammalian tmACs, in contrast, are not responsive to
bicarbonate but are mainly regulated by heterotrimeric G-proteins [10].
The regulation of tmACs has been reviewed extensively (see, e.g., Refs.
[5,10,85]) and will be discussed here only in comparison to sAC
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general regulation features of sAC-like enzymes and on mechanisms
applying to mammalian sAC enzymes, but not on mechanisms speciﬁc
for sAC enzymes from lower organisms.
2.4.1. Physiological regulation
2.4.1.1. Isoform expression and localization. The single conﬁrmed
mammalian sAC gene and the nine mammalian tmAC genes encode
isoformswith distinct regulation. They show different tissue expression
patterns, which can also depend on the developmental state [85,86].
sAC was initially identiﬁed in testis, where its functional relevance is
long known [14], but it was subsequently also identiﬁed in many addi-
tional tissues [15,20,21,56,87]. Alternative splicing has been reported
for sAC and for several tmAC isoforms, but the physiological signiﬁcance
of the tmAC variants is largely unexplored [4]. For sAC, in addition to a
187 kDa full-length enzyme (sACﬂ) smaller splice variants appear to
be formed. A ~50 kDa sAC form was initially obtained during isolation
of sAC activity from rat testis and termed sACt (sAC truncated) [14]. It
is restricted to the N-terminal part of the full-length protein covering
C1 and C2 and was later found to be formed through alternative splicing
[57]. sACﬂ and sACt are both regulated by Ca2+ and bicarbonate, which
directly act on the catalytic core (see below) [14,57]. However, sACﬂ
appears to display lower basal activity due to the presence of a
small auto-inhibitory module C-terminal from C1 (see Ref. [50] and
below), and its large CTR (see Section 2.1) should mediate additional
sACﬂ-speciﬁc regulation and localization mechanisms that remain to
be established. A physiological role also remains to be identiﬁed for
two sAC splice variants of ~80–85 kDa, which were identiﬁed in several
human tissues and cell lines but would require a partner protein for
activity due to a missing or incomplete C1 domain [4,56].
Subcellular localization contributes to mammalian sAC regulation.
While all tmAC isoforms appear restricted to the cell membrane, sAC
can dynamically localize to different areas of cAMP regulation, such as
the nucleus or mitochondria [22,27,28,74,88,89]. This spatio-temporal
distribution of sAC contributes to the dynamic formation of intracellu-
lar, locally restricted cAMP signaling domains through interplay with a
large variety of cAMP-degrading PDEs [8,22,89–91]. The different regu-
lation of PDEs, tmACs and sAC isoforms, and their tissue-speciﬁc and
dynamic expression and localization provides differently regulated
and localized cAMP signaling systems, explaining how cAMP can
regulate diverse, and sometimes seemingly contradicting processes
even within a single cell type [22,88]. However, the exact signals and
mechanisms mediating intracellular sAC relocation remain to be
identiﬁed.
2.4.1.2. Regulatory domains and proteins. The main regulators of tmACs
are heterotrimeric G-proteins, whereas no regulatory proteins have
yet been identiﬁed for mammalian sAC. Gα subunits bind directly to
tmAC catalytic domains, leading to stimulation of all tmAC isoforms by
the Gs α-subunit (Gsα), and inhibition of tmACs 1, 5, and 6 in case of
Goα or Giα [10]. All available heterodimeric tmAC structures comprise
bound Gsα [37], making it difﬁcult to deduce the effects of its binding.
However, comparisons to other AC structures and biochemical data
suggest that G-protein binding inﬂuences stability and relative orienta-
tion of the two catalytic domains and thereby the proper orientation of
the interface residues forming the active site [42,49]. Such a subunit
rotation is assumed to constitute a major mechanism in Class III AC
regulation [4,42] andwas also proposed, e.g., for regulation of a bacterial
AC by a pH-sensing domain [48] (see below). Despite the structural
similarity of sAC to tmACs (see Section 2.2), smaller sAC-speciﬁc
features likely explain its G-protein insensitivity. The C2-α1/α2* loop
as a major Gsα binding region in tmACs is shortened in sAC (and α1
in fact not present) [19]. Likewise, the extended tmAC C2–α3/β3* loop
implicated in Gβγ binding, which can have an activating or inhibiting
effect on several tmACs [10,92], is missing in sAC [19,45]. The otherway round a ~8 residue insertion in the sAC α1/α2 loop, which was
mapped as Giα binding site through mutagenesis, should hinder such
an interaction with sAC. Other tmAC regulator proteins are RGS2 and
Ca2+/calmodulin [10], and while tmAC regions contributing to the in-
teraction with Ca2+/calmodulin have been mapped (see Section 2.1),
no details are known about these interactions.
tmACs can be affected by S-nitrosylation and N-glycosylation, and in
particular, several isoforms are phosphorylated and regulated by CaM
kinase, PKA, PKC, or receptor tyrosine kinases [4,10,85]. For sAC,
the only PTMs reported so far are phosphorylations. Several sAC
residues were indicated as potential phosphorylation sites in mass
spectrometry-based phosphoproteomics studies, but only three of
them were identiﬁed in at least two such large scale experiments [93].
Tyr268 in the C1–C2 linker is oriented into the core of the NLH-bundle,
and its phosphorylation might indicate dynamic rearrangements for
this region. Thr1132 and Tyr1134 are located in the functionally
uncharacterized putative TPR region [93]. The relevance of these
phosphorylations for regulation of sAC activity or localization remains
to be analyzed.
A variety of domains can be fused to Class III catalytic domains
(see Section 2.1) and regulate AC activity or localization directly or
through interaction with regulatory proteins. Examples comprise a
regulator domain mediating pH sensing, and possibly also fatty acid-
dependent regulation, in mycobacterial ACs and a MASE2 containing
N-terminus in the bicarbonate activated CyaB from P. aeruginosa
(see also Section 2.1) [36,48,94]. The pH sensing domain is the only
case of structurally characterized fusion of catalytic and regulatory
domains. The pH sensor appears to prevent proper orientation of the
two catalytic domains in the inactive state and to promote a relative ro-
tation of the catalytic domains in an active state through a helix-to-loop
transition of the linker to the regulatory module [48]. Such an effect on
the relative orientation of the catalytic domains is also assumed to
contribute to tmAC regulation by G proteins (see above). The MASE2
domain in CyaB obviously targets the protein to the cell membrane,
but the very N-terminus, C1–C2 linker, and a C-terminal extension also
inﬂuence CyaB activity and its regulation by the protein PilG, yet the
mechanisms remain to be established [36]. Similarly, the tm modules
dominate the regions outside the catalytic domain in mammalian
tmACs and only small stretches contribute, through unknown mecha-
nisms, to regulation, e.g., by Ca2+/calmodulin (see Section 2.1 and
Ref. [85]). In mammalian sAC, a large ~1100 residue CTR appears to
comprise several domains (see Section 2.1), but only two regions have
been studied in more detail. A nine residue region immediate
C-terminal to C2 was proposed as an auto-inhibitor module based on
deletion constructs and was suggested to cause the lower basal activity
of sACﬂ as compared to sACt that ends after C2 [50]. A mutagenesis
screen revealed three substitutions relieving autoinhibition [50], and
the sAC structure shows that they locate to the end of β8, which partic-
ipates in the putative catalytic closure movement (see Section 2.2.2),
and contribute to packing against β7 and the bulk catalytic core [19].
Interestingly, a similar screen also identiﬁed an activating mutation in
the corresponding region of the bacterial sAC-like CyaB [36], and it
will be interesting to see how this region regulates the catalytic
domains, alone or in combination with other domains (such as STAND
domains in mammalian sAC — see Section 2.1) or proteins (such as
the CyaB regulator PilG).
2.4.1.3. ATP and GTP. Mammalian sAC and other sAC-like AC show a
low apparent ATP afﬁnity, with a KM around 10 mM in presence of
Mg2+, which is two orders of magnitude lower than typically
observed for other Class III AC [4]. The low substrate afﬁnity of sAC
appears relevant for two regulation mechanisms. It enables activa-
tion by Ca2+, which increases the apparent afﬁnity (see below),
and it allows sAC to serve as an intracellular ATP sensor by rendering
its activity sensitive to physiological changes in ATP concentrations
(typically 1–3 mM) [18]. The loss of a polar interaction to the
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like AC has been proposed to be mainly responsible for this typical sAC
feature (see Refs. [19,45] and Section 2.2). The lower apparent ATP afﬁn-
ity of sAC might also contribute to an inhibitory binding mode that is
speciﬁcally observed for sAC enzymes and causes substrate inhibition
at ATP concentration above 5 mM [16,17]. However, a physiological rel-
evance of substrate inhibition and the molecular details involved in this
effect remain to be established.
GTP appears to bind with similar afﬁnity as ATP to the active site
of sAC, and possibly other ACs, followed by slow turnover (see Refs.
[19,45] and Section 2.2). Crystallization of a sAC/GTP complex has
not been successful so far, but the absence of adenine-speciﬁc inter-
actions in sAC complexes with ATP or ATP analog likely explains the
lacking discrimination during binding (see Refs. [19,45] and
Section 2.2). GTP thus might cause competitive inhibition under
physiological conditions, since cellular GTP concentrations appear
to be slightly lower but in the same order of magnitude as ATP con-
centrations [95]. Interestingly, ATP can bind to one of the two active
sites of homodimeric mammalian receptor GCs, which appears to
contribute to their physiological activation [96]. The sites are directly
neighboring to each other and possibly further coupled through dimer
rotation (see above). The half-of-the-site activity and spontaneous
functional diversiﬁcation for two identical sites in homodimeric
bacterial Class III cyclases (see below, bicarbonate) also support a
regulatory function and coupling of the second active site. However,
a GTP binding to the regulatory site of sAC can be excluded due to
steric restrictions, and a physiological relevance of sAC inhibition
through GTP binding to its active site remains to be shown.
The mammalian sAC CTR with its putative NTPase domain might
mediate a second, so far uncharacterized nucleotide-dependent regula-
tion mechanism (see Section 2.1). Again, a functional analogy might be
observed for mammalian receptor GCs, where a kinase homology
domain appears to contribute to ATP-dependentmodulation of receptor
activation [97].
2.4.1.4. Ca2+. tmAC and sAC-like AC can be either activated or inhibited
by Ca2+. Activation of tmAC 1 and 8 is mediated by Ca2+/calmodulin,
which appears to bind to regions in the tmAC N- and C-terminus [85].
Low micromolar concentrations of free Ca2+ selectively inhibit tmAC
5 and 6, whereas high concentrations (mM) inhibit all tmACs [85].
Both effects appear to be caused by Ca2+ binding in the ionA/B region
[67], suggesting that differences in the surrounding of the conserved,
ion coordinating Asp pair (see Section 2.2) inﬂuence the binding of
ions and/or substrate. Indeed, sAC-like ACs also feature the Asp pair
but show a unique regulation by Ca2+. In contrast to tmACs, Ca2+
alone, in absence of Mg2+ and Mn2+, enables low sAC activity [45].
More importantly, Ca2+ stimulates the Mg2+-dependent activity of
sAC-like ACs, an effect that appears to modulate cAMP formation,
e.g., in mitochondria and in sperm and insulinoma cells [31,98,99].
Although in vitro Ca2+ activation saturates only at high micromolar
concentrations, signiﬁcant stimulation of sAC activity is already
observed with submicromolar Ca2+ [16,56]. Biochemical and structural
studies show that Ca2+ activates sAC and its homologues through bind-
ing to the ion B site, where it functions as a stronger interaction partner
than Mg2+ for the βγ-phosphates of ATP [17,19]. Thereby, it increases
the apparent substrate afﬁnity, reﬂected by a lowering of the KMATP in
presence of Mg2+ from ~10 mM to ~1 mM through Ca2+ addition
[16,17]. Physiological sAC activity thus appears optimally supported by
Mg2+ in the ion A site and Ca2+ in the ion B site. Interestingly, studies
on sAC protein immunoprecipitated from testis or overexpressed in
HEK293 cells indicated a biphasic activation in response to increasing
Ca2+ concentrations [99]. An initial phase of Ca2+-induced doubling
in sAC activity was observed in the range of 10 nM to 10 μM, due to
an increase in vmax rather than a lowering in KMATP. This potent Ca2+ ef-
fect was also independent of calmodulin and required only the catalytic
domains [99], suggesting that it might also be mediated via the ionA/Bsites. It remains to be seen, however, whichmechanisms andmolecular
features, such as PTMs, might be responsible for this additional sAC
activation effect.
2.4.1.5. Bicarbonate and forskolin. A deﬁning property of sAC-like AC is
their activation through bicarbonate binding [15,17], which makes
them the only signaling proteins known to be directly regulated by
bicarbonate. The equilibrium between bicarbonate and CO2 and its
role in pH homeostasis also enables them to sense changes in pH
and CO2 [100]. The EC50 for stimulation is in the range 10–25 mM,
appropriate for sensing the physiological bicarbonate levels of 2 to
25 mM [15,16,100]. tmACs are bicarbonate-insensitive and instead
can be activated by forskolin [10], a plant diterpene. Forskolin
binds in the second, degenerated “active site” (Figs. 2a and 4a),
which is speculated to constitute the binding site for a yet to be iden-
tiﬁed endogenous tmAC regulator [42,49]. Forskolin-dependent
activation appears to involve dimer stabilization and smaller active
site rearrangements [42], but details remain speculative since
forskolin-free tmAC structures are not available [37]. Mammalian
sAC is insensitive to forskolin [14], since Arg176 (replaced by Ala in
tmACs) and a four residue insertion in the β2/3* loop restrict the
space available in its second, degenerated “active site” (Figs. 2a and
4b) [19]. This sAC site instead accommodates the smaller sAC-
speciﬁc activator bicarbonate [19,61]. The activator binds between
Lys95 and Arg176, which is thereby released from an inhibitory in-
teraction with the conserved active site residue Asp99 and acts as a
trigger arm connecting catalytic center and regulatory bicarbonate
binding sites (BBS; Fig. 4b). Bicarbonate thereby enables rearrange-
ments of Asp99 and additional active site residues that allow ion
site formation and that closely resemble changes also observed
upon substrate binding [19]. The kinetic effect of bicarbonate ap-
pears to be an increase in turnover [16,17], however, indicating
that substrate binding and turnover might indeed be tightly coupled
(see Section 2.2.2) or that some features of bicarbonate-dependent
activation could not be detected with this sAC crystal form. In fact,
soaking experiments with bicarbonate and crystals of sAC/ATP ana-
log complexes led to crystal dissolution, indicating conformational
changes not compatible with the packing of these crystals [19]. Pre-
vious bicarbonate soaking experiments with crystals of the sAC-like
AC CyaC in complex with ATP analogs showed an induced active
site closure of β7/8 and α1, and this open-closed transition was pro-
posed to be part of the general mechanism of substrate turnover (see
Section 2.2.2) [17]. Based on mammalian sAC binding data, it has
been speculated that bicarbonate might affect release of the product
PPi, possibly by inﬂuencing this open-closed transition (see
Section 2.2.2 and Ref. [19]). The packing of human sAC crystals
might hinder movements of α1 and β7/8, but the sAC crystals
retained activity and it remains to be clariﬁed whether this or other
movements are indeed essential for sAC catalysis and bicarbonate-
dependent stimulation.
Interestingly, CyaC and other homodimeric sAC-like AC have two a
priori identical sites yet are bicarbonate regulated similar to human
sAC [17]. Apparently, the two sites can act as regulatory or catalytic
site, depending on the order of binding events. Such an asymmetry
and coupling of sites during catalysis are supported by half-of-the-
sites reactivity reported for two bacterial homodimeric Class III cyclases
[38,101] andmight be an evolutionary state before gene duplication and
optimization of the second site for regulator binding. A consequence of
combined functions as active and regulatory site appears to be similar-
ities between such sites but also less optimal arrangements in homodi-
meric enzymes. Of the two positively charged, bicarbonate recognizing
residues in human sAC Lys95 is conserved in all sites because the corre-
sponding residue in active sites contributes to catalysis. Human sAC
Arg176, in contrast, is not exactly conserved in bacterial sAC-like AC
but might be functionally replaced by the neighboring catalytic CyaC
residue Arg1150* [17,19,45]. It is tempting to speculate that this residue
Fig. 4. Physiological and pharmacological sAC regulation. (a) Overlay of the regulator binding sites of activator complexes of sAC (cyan; PDB ID: 4CLL) and tmAC (green; 1CJT). The tmAC
activator forskolin (sticks)would clashwith sAC-Arg176 (sticks; labeled) and the extended sACβ2/3* loop (labeled). The smaller sAC activator bicarbonate (sticks; yellow carbon, labeled)
is bound at the edge of the tighter sAC regulator pocket. (b) The overlay of apo sAC (cyan; 4CLF) and a sAC/bicarbonate complex (yellow; 4CLL) shows the rearrangements of Arg176 and
Asp99 upon bicarbonate (sticks) binding. Selected secondary structure elements are labeled. (c) Chemical structures of the pharmacological sAC inhibitors 2-CE, BCC8, ASI-8, and KH7.
ASI-8 appearsmost potent, and KH7 is best characterized and shows a potent and speciﬁc effect. (d) Crystal structure of the sAC-like ACCyaC in complexwith 2-CE (2BW7). The compound
(sticks, bottom) interactswith theMg2+ ion A (orange), resulting in a non-productive complexwith Ca2+ (yellow) and ATP analog (sticks, top). The ligands from the symmetric active site
have been omitted for clarity. (e) Crystal structure human sAC-cat in complex with ASI-8 (4OYA). The inhibitor (sticks) occupies the center of the catalytic core (orientation as in Fig. 2a)
and extends in the BBS at the lower left.
2543C. Steegborn / Biochimica et Biophysica Acta 1842 (2014) 2535–2547shifted during evolution to optimize bicarbonate binding after itwasnot
required anymore for transition state stabilization.
More recently, bicarbonate-dependent stimulation was also report-
ed for Class III GCs, in particular the mammalian receptor GC isoforms
D andG [102–104]. Like in sAC, the catalytic domains of theseGCs appear
directly targeted by bicarbonate, but the Arg/Lys pair recognizing bicar-
bonate in sAC-like ACs is not conserved and the mechanism for their
bicarbonate-dependent stimulation remains to be established. Further-
more, a recombinant tmAC catalytic domain heterodimer was reported
to be activated by CO2 rather than bicarbonate, but further studies will
be required to test the physiological relevance of this effect [105].2.4.2. Pharmacological regulation of sAC-like enzymes
cAMP is a ubiquitous signaling molecule contributing to many
physiological functions. The established clinical application of inhibitors
for the AC opponents, PDEs, veriﬁes the suitability of modulating cyclic
nucleotide signaling for therapy [28,106]. Since distinct AC isoforms
contribute to speciﬁc processes they are also explored as therapeutic
targets [34]. Pharmacological modulation of tmACs is considered,
e.g., for the treatment of asthma and congestive heart failure [34], but
these efforts are still in early research phases and suitable drug-like
compounds largely remain to be identiﬁed (see Refs. [34,107] and
below). More extensive research efforts on mammalian sAC started
2544 C. Steegborn / Biochimica et Biophysica Acta 1842 (2014) 2535–2547only ~15 years ago [14,15], and we are just beginning to recognize sAC
as an essential component ofmanymammalian cAMP signaling systems
[4,100,108]. Thus, the potential of sAC as therapeutic target is only
emerging. sAC promotes keratinocyte hyperproliferative skin diseases
and is used as a diagnosticmarker and drug development target for pso-
riasis and squamous cell carcinoma [35,109]. sAC mutations have been
linked to hypercalciuria, which causes kidney stone formation and
bone loss [110], and sAC was suggested as a potential target for a male
contraceptive, type 2 diabetes, glaucoma, and prostate cancer [31,32,
34,111]. Furthermore, sAC-like ACs were found to regulate virulence
mechanisms of human pathogens such as P. aeruginosa, C. albicans,
and Plasmodium falciparum [30,36,84,112]. First compounds show that
speciﬁc inhibition of the microbial sAC enzymes versus host sAC can
be achieved [36,112], and that inhibition of the pathogens' sAC en-
zymes, and the bicarbonate/CO2-sensing systems they form, are prom-
ising approaches for the development of novel anti-infectives [84,112,
113].
For using AC as drug targets, but also for functional studies on cAMP
signaling, it is important to pharmacologically distinguish related Class
III enzymes, such as tmAC and sAC or host and pathogen AC. A variety
of Class III AC inhibitors has been described, and in particular character-
ized for tmACs, but most of them are either not suitable as drugs and
were used for mechanistic or proof-of-principle studies, or they lack
sufﬁcient isoform selectivity [107]. However, the ﬁrst encouraging
results on selectively modulating Class III ACs and on using them as tar-
gets should now stimulate and support such development efforts
[34,114,115]. Here, an overview of available compound classes will be
given, with an emphasis on their effects on sAC.
2.4.2.1. ATP, ATP-analogs, GTP, and P-site inhibitors. sAC-like ACs show a
lower apparent ATP afﬁnity than other Class III AC, which enables ATP
sensing and Ca2+ activation (see Section 2.4.1). Small differences
between sAC and tmAC appear to cause this sAC-speciﬁc property,
while the general binding site geometry and interactions are very
similar (see Section 2.2). Consistently, complexes of sAC and tmAC
with close ATP analogs such as ApCpp and Rp-ATPαS are highly compa-
rable and revealed general insights in substrate binding and catalysis
(see Section 2.2) [17,19,66]. Some smaller differences between com-
plexes appear to bedue to the differentmodiﬁcations of thenucleotides,
rather than the different AC enzymes, and revealed further mechanistic
insights [4,17]. CyaC complexes with Rp-ATPαS and α,β-Me-ATP,
respectively, revealed that replacing the αP-pro-R oxygen causes
ATPαS to bind with the pro-S oxygen to ion A, resulting in a nucleotide
conformation that prevents the in-line attack of the 3′-hydroxyl group
(see Section 2.2.2) [17]. In Sp-ATPαS, in contrast, the unmodiﬁed pro-
R oxygen can bind to ion A, which results in an arrangement suitable
for the in-line reaction and explains why Class III ACs are inhibited by
the Rp isomer of ATPαS, whereas the Sp form is a substrate [17,65].
α,β-Me-ATP, which features both oxygens as in the real substrate ATP,
indeed binds with the pro-R oxygen to ion A and in the conformation
required for the in-line reaction [17,19].
ApCpp and ATPαS are closely related to ATP, a substrate for
hundreds of cellular proteins, and they are thus not useful as pharmaco-
logical compounds. A more selective class of adenosine derived com-
pounds belongs to the so-called P-site inhibitors and comprises
compounds such as 2′,5′-dideoxyadenosine-3′-tetraphosphate and
3′-AMP [68,69,107]. They potently inhibit tmACs non-competitively,
apparently through tight binding to the active site conformation of the
PPi product complex, resulting in a dead-end complex [68]. The sAC
features causing its lower apparent ATP afﬁnity (see Section 2.2)
might be responsible for sAC's lower sensitivity to inhibition by some
P-site ligands [115]. Non-nucleoside P-site inhibitors, in particular
PMC-6 (1R,4R-3-(6-aminopurin-9-yl)-cyclopentanecarboxylic acid
hydroxyamide), can combine signiﬁcant potency and tmAC isoform
selectivity with membrane permeability, demonstrating the potential
of P-site inhibitors for drug development [107,116].Another class of inhibitory nucleotides are 2′(3′)-O-(N-
methylanthraniloyl) (MANT)-substituted derivatives. They are
more potent against tmACs than against sAC, but with limited
tmAC isoform selectivity, and they were mainly used for mecha-
nistic studies [107]. However, MANT nucleotides block the ATP
binding site but position the MANT ﬂuorophore in a less conserved
hydrophobic pocket at the C1/C2 interface, and further developing
ligands with moieties in this site might yield pharmacologically useful
compounds with improved isoform speciﬁcity [117].
2.4.2.2. Forskolin derivatives, bicarbonate, and DIDS. The plant diterpene
forskolin activates mammalian tmACs 1–8, but not sAC, through not
fully understood mechanisms induced by binding to the degenerated
“active site” (see Refs. [10,14,42,49] and Section 2.4.1). Some forskolin
derivatives indicated potential of this compound class for the develop-
ment of isoform speciﬁc activators [114], but the incomplete mechanis-
tic understanding and the availability of only one crystallizable
mammalian tmAC catalytic core system have hampered such efforts.
The physiological activator of sAC-like AC, bicarbonate and Ca2+, is
not suitable as pharmacological sAC activator due to instability and
non-speciﬁc pH effects (bicarbonate) and the multitude of effectors
(Ca2+). While unlikely for the Ca2+ site, the development of speciﬁc
pharmacological ligands for the BBS sitemight be conceivable, in partic-
ular if neighboring pockets are also exploited, and should yield sAC
speciﬁc activators, inhibitors, or blockers of bicarbonate stimulation.
Two types of sAC inhibitor complexes identify such binding opportuni-
ties close to theBBS. Fragment-based screens identiﬁed several inhibito-
ry ligands for a channel toward the BBS, including a potently inhibiting
benzoimidazole (see Ref. [61] and below). The second sAC complex
structure comprises 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid
(DIDS), a compound known to block bicarbonate transporters [19].
The compound was tested based on the idea that its sulfonic acid moie-
ties might occupy the BBS, and it turned out to be a moderately potent
sAC inhibitor. It binds to an active site entrance funnel with positive
surface potential and blocks entrance and channel to the BBS, but it
does not occupy the BBS itself [19]. The sAC/DIDS interactions appear
far from optimal, suggesting that much more potent inhibitors can be
developed based on this compound and inhibition mode. Furthermore,
the neighborhood to the BBS might allow the development of speciﬁc
activators by exploiting both binding sites.
2.4.2.3. Catechol estrogens, tyrphostins, and other ion chelators. Catechol
estrogens (CEs) are physiologically occurring steroid derivatives that
can inhibit mammalian AC enzymes [118]. 2-Hydroxy estradiol (2-CE;
Fig. 4c) and 4-hydroxy estradiol (4-CE) inhibit puriﬁed mammalian
sAC and CyaC potently (IC50 values 2–8 μM), but they inhibit some
puriﬁed tmAC isoforms with comparable potency [118]. Interestingly,
CEs are more selective for sAC versus tmACs when membrane prepara-
tions or cellular systems are used, with sAC still being signiﬁcantly
inhibited but the potency against tmACs dropping dramatically [115,
118]. The reason for this behavior is unclear, but it appears to render
CEs suitable for distinguishing between sAC and tmAC in cellular
systems.
CEs are present in several tissues and can inhibit cAMP accumula-
tion in the hypothalamus [119,120], but a role as physiological sAC
regulators appears less likely based on their levels and potency.
Nevertheless, CEs appear interesting starting points for sAC-targeted
drug development. Biochemical studies and crystal structure analysis
of a CyaC/substrate analog/2-CE complex showed that CEs inhibit
sAC-like AC non-competitively. They bind to a rather hydrophobic
patch within the dimer center and next to the active site, where they
chelate and shift the catalytic ion A and thereby trap an enzyme-
substrate complex in a non-productive conformation (Fig. 4d) [118].
Variations between AC isoforms in the CE binding pocket suggest that
more speciﬁc ligands can be developed, and a structure-based virtual
screen with CyaC indeed yielded two inhibitors for CyaC and human
2545C. Steegborn / Biochimica et Biophysica Acta 1842 (2014) 2535–2547sAC (IC50 values 1 and 11 μM, respectively, against human sAC) with
negligible effects on several tmAC isoforms [121]. These compounds,
3,20-dioxopregn-4-en-21-yl 4-bromobenzenesulfonate (BCC2)
and 1,2,3,4,5,6,7,8,13,13,14,14-dodecachloro-1,4,4a,4b,5,8,8a,12b-
octahydro-11-sulfo-1,4:5,8-dimethanotriphenylene-10-carboxylic
acid (BCC8), are not suitable for in vivo studies but show that there are
additional scaffolds that can exploit the CE site in an isoforms speciﬁc
manner. In principle, this binding site region should also allow speciﬁc
inhibition of tmAC isoforms, and a CE-like binding mode was indeed
predicted for the tmAC1/6-speciﬁc compound CB-7921220 [122].
Several other AC inhibiting compounds might also exploit the CE bind-
ing site and inhibition mode. A variety of catechols, such as dopamine
and apomorphine, likely exert their sAC inhibiting effects via the CE
mechanism [118,123]. The same likely applies to the catechol moiety-
containing members of the tyrphostin family of kinase inhibitors,
which inhibit mammalian Class III cyclases non-competitively [124].
The most potent representative, tyrphostin A25 (a.k.a. AGK82), inhibits
mammalian GC-C with an IC50 of 5.8 ± 2 μM and shows weaker effects
on tmAC and sGC activity. A CE-like mechanism appears more specula-
tive for calmidazolium, a chelating compound without catechol moiety
and with a non-speciﬁc modulatory effect on several tmAC isoforms
[107,125].
2.4.2.4. Other compound classes, in particular KH7 and other
benzoimidazoles. A small number of compounds from chemical clas-
ses not covered above have been described as tmAC inhibitors, but
they show limited potency and/or speciﬁcity [107]. Potent sAC inhib-
itors, in contrast, have been identiﬁed in two screening efforts. (E)-2-
(1H-Benzo[d]imidazol-2-ylthio)-N′-(5-bromo-2-hydroxybenzylidene)
propanehydrazide (KH7; Fig. 4c) was identiﬁed as a potent sAC inhibi-
tor (IC50 ~3 μM) through a high-throughput chemical library screen [59,
115]. KH7 shows good membrane permeability and has no signiﬁcant
effect on tmACs [59,115], yet weakly activates sGC at higher concentra-
tions (Steegborn and Buck, unpublished). KH7 has been used as phar-
macological tool in many sAC studies and seems promising as a lead
compound for drug development.
KH7 and closely related derivatives also inhibit sAC-like enzymes
from microbial organisms and might allow the development of anti-
infectives. KH7 potently inhibits the sAC-like ACβ from P. falciparum
(PfACβ) and kills thismalaria-causing pathogen [112]. A KH7 derivative,
KH7.15, inhibits PfACβ, and kills P. falciparum, with lower potency but
shows no effect on mammalian sAC. These ﬁndings suggest PfACβ as a
novel anti-malaria target and KH7 derivatives as promising compounds
for drug development since they can potently inhibit the pathogen's AC
but also distinguish it from host ACs [112]. The parent compound, KH7,
inhibits sAC-like AC from many organisms but showed no signiﬁcant
effect on the bicarbonate-activatedAC CyaB from the bacterial pathogen
P. aeruginosa [36]. However, screening a library of KH7 derivatives iden-
tiﬁed KH7.148 as a CyaB inhibitor (IC50 ~10 μM) with a much weaker
effect on mammalian sAC (IC50 N100 μM) [36]. These results show
again that the KH7 scaffold allows potent inhibition of sAC-like AC and
furthermore bears the potential to discriminate between such ACs
from different organisms, in particular pathogen and host.
The KH7 binding site andmechanism for sAC inhibition have not yet
been identiﬁed, but they likely resemble those of another, recently iden-
tiﬁed group of sAC inhibitors. A fragment-based screening approach by
Astex Pharmaceuticals initially yielded smaller compounds binding in
the BBS or next to it and inhibiting human sAC weakly or moderately
(IC50 values 19 to N300 μM) [61]. An amino-furazan from these initial
hits was further developed into potent inhibitors for human sAC
through a “growing” approach, with the most potent compound (4-
Aminofurazan-3-yl)-[3-(1H-benzoimidazol-2-ylmethoxy)phenyl]
methanone (Astex sAC inhibitor 8, ASI-8; Fig. 4c) inhibiting with an
IC50 of 0.36 μM. A crystal structure of a sAC-cat/ASI-8 complex
shows that the compound occupies the BBS and the channel
connecting it to the active site (Fig. 4e) [61]. This binding modesuggests that the compound will be selective for sAC and sAC-like
AC, but activity data on AC selectivity, in particular on effects against
mammalian tmACs, are not yet available. Also, the inhibition mecha-
nism of these compounds remains to be fully understood. The larger
compounds partially overlap with the ATP binding site, but this does
not apply to smaller precursors already showing signiﬁcant inhibito-
ry effects, which suggests more subtle mechanisms coupling regula-
tory and active site. The sAC-speciﬁcity of KH7 [4,59] might indicate
that it also occupies the BBS, and the benzoimidazole moity and
overall length it shares with ASI-8 might also hint at an ASI-8-like
binding mode, but the exact binding and inhibition modes of KH7
remain to be established.
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